Treatment Patterns of Atopic Dermatitis Medication in 0-10-Year-Olds: A Nationwide Prescription-Based Study.

Autor: Mohn CH; Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. c.h.mohn@medisin.uio.no., Blix HS; Department of Drug Statistics, Norwegian Institute of Public Health, Oslo, Norway.; Department of Pharmacy, The Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway., Brænd AM; Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway., Nafstad P; Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.; Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway., Nygard S; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Oslo, Norway.; Department of Research, Cancer Registry of Norway, Oslo, Norway., Halvorsen JA; Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.; Department of Dermatology, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Jul; Vol. 12 (7), pp. 1639-1657. Date of Electronic Publication: 2022 Jun 28.
DOI: 10.1007/s13555-022-00754-6
Abstrakt: Introduction: The literature on treatment patterns for paediatric atopic dermatitis (AD) is scarce and is rarely based on real-world data. Using national registers, we sought to establish up-to-date, population-based prevalence estimates, predictors of risk and disease burden and a comprehensive overview of treatment patterns and course for paediatric patients with AD.
Methods: Dispensed prescriptions for the entire Norwegian child population aged 0-10 years from 2014 to 2020 were analysed.
Results: There were 176,458 paediatric patients with AD. Of these, 99.2% received topical corticosteroids, 5.1% received topical calcineurin inhibitors, 37.1% received potent topical corticosteroids and 2.1% received systemic corticosteroids. Of the 59,335 live births in Norway (2014), 14,385 [24.8%; 95% confidence interval (CI) 24.5-25.1] paediatric patients were treated for AD before the age of 6 years, and of these, only 934 (6.5%; 95% CI 6.1-6.9) received medication annually for 5 years or more. Compared with girls, 17.9% (95% CI 6.5-27.9) more boys were treated for at least 5 years, receiving 6.4% (95% CI 1.2-11.3) more potent topical corticosteroids and 12.4% (95% CI 6.5-18.0) more were treated for skin infections. Compared with patients with late-onset treatment, 18.9% (95% CI 7.5-29.0) more paediatric patients with early-onset treatment were still receiving treatment at 5 years of age, 15.7% (95% CI 7.1-23.4) more paediatric patients received potent topical corticosteroids and 44.4% (95% CI 36.5-51.2) more paediatric patients were treated for skin infections.
Conclusion: Most paediatric patients were treated for a mild disease for a limited period. Although the prevalence of AD is higher at a younger age, these paediatric patients were the least likely to receive potent topical corticosteroids. Male sex and early-onset AD are associated with and are potential predictors of long-term treatment and treatment of potent topical corticosteroids, antihistamines and skin infections, which may have clinical utility for personalised prognosis, healthcare planning and future AD prevention trials.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje